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Abstract
Apicomplexan parasites are responsible for a myriad of diseases in humans and livestock; yet despite intensive effort,
development of effective sub-unit vaccines remains a long-term goal. Antigenic complexity and our inability to identify
protective antigens from the pool that induce response are serious challenges in the development of new vaccines. Using a
combination of parasite genetics and selective barriers with population-based genetic fingerprinting, we have identified
that immunity against the most important apicomplexan parasite of livestock (Eimeria spp.) was targeted against a few
discrete regions of the genome. Herein we report the identification of six genomic regions and, within two of those loci, the
identification of true protective antigens that confer immunity as sub-unit vaccines. The first of these is an Eimeria maxima
homologue of apical membrane antigen-1 (AMA-1) and the second is a previously uncharacterised gene that we have
termed ‘immune mapped protein-1’ (IMP-1). Significantly, homologues of the AMA-1 antigen are protective with a range of
apicomplexan parasites including Plasmodium spp., which suggest that there may be some characteristic(s) of protective
antigens shared across this diverse group of parasites. Interestingly, homologues of the IMP-1 antigen, which is protective
against E. maxima infection, can be identified in Toxoplasma gondii and Neospora caninum. Overall, this study documents
the discovery of novel protective antigens using a population-based genetic mapping approach allied with a protection-
based screen of candidate genes. The identification of AMA-1 and IMP-1 represents a substantial step towards development
of an effective anti-eimerian sub-unit vaccine and raises the possibility of identification of novel antigens for other
apicomplexan parasites. Moreover, validation of the parasite genetics approach to identify effective antigens supports its
adoption in other parasite systems where legitimate protective antigen identification is difficult.
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Introduction
The protozoan phylum Apicomplexa contains pathogens of
substantial medical and veterinary importance including Plasmo-
dium, Toxoplasma, Cryptosporidium, Eimeria, Neospora and Theileria
species. Despite several decades of effort vaccines protective
against these and other related parasites are scarce. Empiric
approaches to identify genuinely immunoprotective antigens as
vaccine candidates have achieved mixed results (e.g. [1,2]) and
problems differentiating immunogenicity from real immune
protection persist. Here we report the culmination of our efforts
to develop a new approach to candidate antigen identification, one
based upon using immunity as a selective barrier allied with
pathogen genetics and mapping to identify true immune-targeted
loci. Having identified candidate genomic regions we used a
variety of strategies to locate the antigen responsible for protection.
This approach has yielded new protective antigens for Eimeria
maxima, one of the most important apicomplexan parasites to
afflict livestock and provides insight into the nature of protective
antigens in a broader context.
As sustainable food security gains in importance pathogens
which impact upon poultry production are re-emerging as serious
threats to global food supply and human poverty [3,4]. Eimeria
species parasites have a globally enzootic distribution and can
cause severe enteric disease in all livestock, most notably poultry,
where the annual cost is estimated to exceed £2 billion worldwide
[5]. Current control is dominated by prophylactic application of
anticoccidial drugs but drug resistance, political/consumer
concerns over residues and the lack of new pipeline products
renders this an unsustainable approach. Alternatives are limited by
cost and/or efficacy and new solutions are urgently required.
Eimeria are highly immunogenic parasites. Infection with as few
as five E. maxima oocysts can induce complete protective immunity
against subsequent homologous challenge [5]. Conversely, differ-
ent strains of E. maxima can be antigenically diverse such that
infection by one strain can induce little or no protection against
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vivo selection imposed by strain-specific immunity and/or anti-
parasitic medication with a population-based mapping strategy
developed for use with apicomplexan parasites, we and others
have shown that loci affecting strain-specific immunity can be
mapped genetically [6,7,8]. We previously identified a panel of
genetic markers within the E. maxima Weybridge (W) genome
whose inheritance correlated absolutely with susceptibility to
strain-specific immune killing [6]. Here we identify that the genetic
markers associated with immunity map to just six regions
representing less than 0.8% of the genome. Using a combination
of sequencing, fine mapping and vaccination screens we have
identified antigens responsible for protection in two of these loci.
Homologues of both can be found in multiple apicomplexan
parasites and one is known to be protective in diverse parasites of
this phylum including Plasmodium spp. [1]. Hence, the novel
antigens and remaining immune-mapped loci found within this
study will have direct impact on eimerian vaccine development
and have potential to impact on development of new vaccines with
other apicomplexan parasites.
Results/Discussion
The E. maxima Houghton (H) and W strains are genetically and
phenotypically distinct [6]. The H strain is characterised by
sensitivity to dietary robenidine at 66 ppm and complete escape
from W strain-specific immune killing during passage in inbred
Line C White Leghorn chickens (induced by previous host
exposure to the W strain). In contrast, the W strain is resistant
to 66 ppm robenidine but completely susceptible to W strain-
specific immune killing. Genetic characterisation of the E. maxima
H and W strains using amplified fragment length polymorphism
(AFLP) with five different enzyme combinations to minimise
restriction-associated bias generated a total of 3,230 genetic
markers (Table S1). Comparison between the two strains revealed
1,122 markers to be polymorphic (34.7%; considerably higher
than described previously for two Eimeria tenella strains [9]).
Inheritance patterns of these strain-specific (SS) markers by a
parasite mapping panel (Figure 1; Table S2), which included the
uncloned progeny of eight independent H/W strain crosses before
and after concurrent immune/robenidine selection, revealed the
absolute correlation of 36 and 2 markers with the immune and
drug barriers respectively (Figure 2). Importantly, all of the 36
immune correlated markers were subject to strong negative
selection and were completely lost in all independent parasite
lineages. Some other AFLP fragments were found to be less
intensely amplified from immune selected parasites, suggesting
more distant linkage to a mapped locus or linkage to loci
containing genes contributing subtly to the complex biology of
protection, either as modifiers, regulators, or minor antigens. Our
analysis has focussed on the regions marked by AFLP fragments
under the strongest selection by immunity. Serial in vivo passage of
four hybrid populations under double barrier selection for up to
five generations did not change the marker inheritance profile (as
[6]).
Sequencing the 36 SS markers whose inheritance correlated
with susceptibility to strain-specific immune selection identified 32
suitable for use as hybridisation probes (EMBL FN813211-8 and
unpublished). When radiolabeled with
32P and used to probe an E.
maxima W strain BAC library representing ,7.5-fold genome
coverage a total of nine BACs were highlighted (Table 1). Each
BAC was identified by at least two independent markers. BAC end
sequencing and subsequent sequence-specific PCR facilitated the
assembly of these nine BACs into six clusters, representing six
distinct loci (Table 1). BAC insert release by Not I digestion and
resolution by pulsed field gel electrophoresis (PFGE) provided
approximate cluster sizes which were later refined following BAC
insert sequencing and assembly (Table 1; FN813242–4 and
unpublished). Marker hybridisation to Southern blotted full
PFGE-resolved karyotypes identified the chromosomal location
of five of the six clusters (Table 1).
Confirmation of the potent immunogenicity of the early stages
of the E. maxima lifecycle supported the development of an in vivo
BAC-screening system to begin fine mapping for each locus
(Table S3, trial 1). Utilising recent advances in transfection
protocols for Eimeria [10] purified E. maxima H strain sporozoites
were transiently transfected with each individual W strain BAC
identified by hybridisation to an immune-correlated SS marker or
a randomly selected control BAC (Table S3, trial 2). When Line
C chickens were immunised by infection with 1610
6 test-, control-
or non-BAC transiently transfected H strain sporozoites, drug-
cleared by exposure to 66 ppm dietary robenidine to avoid clinical
coccidiosis and challenged three weeks later with the W strain the
capacity to induce cross-protective immunity was conferred by
BACs derived from five of the six mapped loci (Table 1). In three
independent experiments BACs representing loci 2 and 5
consistently induced the highest levels of immune protection,
followed by BACs from loci 1, 3 and 4 (Table 1). No cross-
protective phenotype was observed using the sixth locus,
suggesting either a mapping error, a requirement for a strain-
specific partner molecule (encoded elsewhere in the genome) or
stage-specific antigen expression towards the latter stages of the E.
maxima lifecycle. The transient nature of our transfection approach
is such that that if a protective antigen or other protection-
affecting element was not expressed before loss of the host BAC
then protection would not be detected. The six loci under intense
immune selection (i.e. essential loci) are dispersed across the E.
maxima genome (Table 1). Importantly, BAC-transfection based
vaccination with five of the loci induced strain-specific immunity,
indicating that each can act independently. Having identified
relevant polymorphisms we can use this information to perform
Author Summary
Protozoan parasites are responsible for serious diseases in
humans and livestock species. Vaccination is a declared
intervention of choice with these infections, but even after
many years of effort few effective vaccines are available.
Identification of the right antigens for inclusion in sub-unit
vaccines is a particular problem with complex pathogens.
Moreover, the host response does not discriminate
between protective and non-protective antigens, con-
founding development of effective screening systems. This
study represents the culmination of work using parasite
genetics and immunity as a selective barrier to find parts of
the parasite genome targeted by immunity. The pathogen
used in these studies (Eimeria maxima) is very important in
livestock and related to a number of human pathogens
including those responsible for malaria. Our studies
indicate that just six regions in the genome were targeted
by immunity and two of these have now been interrogat-
ed to determine the protective antigen encoding gene.
Interestingly, one of these (called AMA-1) has homologues
known to be protective with other apicomplexan parasites.
This raises the intriguing possibility that a set of
homologous antigens may be protective across the
apicomplexan parasites and that protective antigen
discovery in one parasite may generate new leads in other
vaccine programmes.
Mapping Protective Apicomplexan Antigens
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population dynamics of the protective-antigen encoding genomic
regions in laboratory and field populations. Preliminary co-
transfection trials using two BAC clones representing loci 2 and
3 induced a higher level of immune protection (83.267.7%
referenced to control BAC transfected parasites) than either
individual BAC (43.1% and 17.1% protection respectively).
Indeed, locus 2/3 co-transfection immunisation gave greater
Figure 1. Production and selection of the parasite mapping panel. All parasite populations shown here were included in the DNA mapping
panel with the exception of those denoted in the black-filled box. All populations shown in the red filled boxes were subjected to immune selection
(6 dietary robenidine selection). The number of replicates per population is indicated in each box.
doi:10.1371/journal.ppat.1001279.g001
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PLoS Pathogens | www.plospathogens.org 3 February 2011 | Volume 7 | Issue 2 | e1001279Figure 2. Eimeria maxima strain-specific traits. (A) Phenotypes. The influence of drug (robenidine) and W strain-specific immunity on H and W
strain parasite replication reveals polymorphic strain-specific selectable traits (H=hollow bars, W=solid bars). (B) Genotypes. The H and W strains
were found to be defined by 588 and 534 strain-specific (SS) AFLP markers respectively. Comparison of AFLP marker profiles amplified from both
parents and the progeny of each independent cross between the H and W strains before and after passage under combined drug and W-specific
immune selection revealed the reproducible loss of between 0 and 36 strain-specific markers. nf=no oocysts found.
doi:10.1371/journal.ppat.1001279.g002
Table 1. Summary of loci mapped within the Eimeria maxima W strain genome associated with susceptibility to strain-specific
immune killing.
Locus No. of No. of ,Mapped BAC size (Kb) (% genome*) Chromosome % protection conferred**
Markers BACs Before backcross After backcross BAC-1 BAC-2 BAC-3
1 3 1 127 (0.21) 45 (0.08) nd 16.0±3.1
a
2 13 2 268 (0.45) 78 (0.13) 13–14 1.361.4 43.6±5.3
b
3 7 3 350 (0.58) 90 (0.15) 3–4 22.561.9 17.1±2.2
a 2.761.7
4 4 1 114 (0.19) 85 (0.14) 5 37.3±2.3
a
5 2 1 90 (0.15) 84 (0.14) 12–14 59.7±6.8
b
6 3 1 145 (0.24) 80 (0.13) 12–14 1.961.1
Total 32 9 1094 (1.84) 462 (0.77) 3–6
Average 5 2 182 (0.30) 77 (0.13) -
*Based upon a predicted 60 Mb genome.
**Immune protection associated with each mapped BAC was measured as the oocyst output resulting from W strain challenge following immunisation by infection with
the heterologous H strain transiently transfected with one candidate BAC compared to transfection with a randomly selected control BAC. Comparison between the
latter and unimmunised birds was not significantly different (5.461.6). The average of three replicate transfections performed on separate occasions is shown. nd=not
done.
aSignificantly different (p,0.01),
bsignificantly different (p,0.005), using ANOVA+Tukey’s post-hoc.
doi:10.1371/journal.ppat.1001279.t001
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studies will explore the combinatorial nature of protection in more
detail.
The parasite mapping panel was supplemented by backcrossing
and re-selecting one double barrier-selected population to the
immune-targeted parental W strain on six successive occasions.
Genotyping each selected backcross generation maintained linkage
with 11/32 SS markers, covering all six loci (e.g. Figure 3A).
Backcross genotyping fine-mapped locus 1 to ,64 Kb of genomic
sequence contained within BAC EmaxBAC8f18. Typing additional
SS PCR markers produced by targeted sequencing from the H
strain across locus 1 provided further focus, mapping the region of
interest to ,50 Kb (Figure 3B, Tables S4 and S5). Bioinfor-
matic examination of fine-mapped locus 1 identified three
predicted coding regions, annotated as encoding (i) a sulphate
transporter, (ii) an apical membrane antigen-1 (AMA-1) homo-
logue and (iii) a transcription elongation factor (Figure 3C).
Sequencing from the H strain identified amino acid polymorphism
in the first two candidates but not the third (FN813219–24). In vivo
infection by H strain sporozoites transiently transfected with
purified genomic Long Distance (LD) PCR amplicons covering
each predicted coding sequence and flanking regions induced a
cross-protective immune phenotype only when using EmAMA-1
(Figure 4). AMA-1 has been widely proposed as an anti-
apicomplexan vaccine candidate [11,12] and the E. tenella
homologue has recently been found to be similarly protective
(Tomley, Billington et al, manuscript in preparation). Immunisa-
tion using EmAMA-1 as a DNA vaccine in the eukaryotic
expression vector pcDNA3.1(+) (Invitrogen) or as a bacterially-
expressed recombinant protein induced significant immune
protection against subsequent challenge by the W strain
(Figure 4). The level of immune protection observed following
immunisation using EmAMA-1 as a DNA vaccine was similar when
challenged with 250 or 2,000 sporulated oocysts (data not shown).
Comparison between the H and W EmAMA-1 coding sequences
revealed four nucleotide polymorphisms, two of which yield non-
synonymous changes, one in the likely pro-domain and one in
domain 1 [13]. Interestingly, AMA-1 domain 1 is also polymor-
phic among Plasmodium falciparum strains and polymorphism in this
region confers the greatest level of escape from inhibitory
antibodies [14]. Immunity induced by exposure to Eimeria spp. is
highly species specific and although the E. maxima and E. tenella
AMA-1 molecules share many structural characteristics the
primary amino acid sequence is considerably different (57% aa
identity). This level of divergence between eimerian AMA-1 is
similar to that observed with Plasmodium AMA-1 from different
species (e.g. P. falciparum compared with Plasmodium vivax, 60% aa
identity).
Whole BAC transient transfection identified locus 5, contained
within BAC EmaxBAC2k08, as capable of inducing the strongest
protective immune response as judged by a reduction of oocyst
production during challenge infection by 59.7% (Table 1).
Backcross genotyping failed to provide any further focus, yielding
a genomic region of interest spanning ,90Kb (Figure 5A–B).
The difference in locus size may reflect variation in genome-wide
recombination rates, as have been reported for other Apicomplexa
[15]. Two parallel approaches were used to focus the search for
protective antigens, one based upon targeted disruption of regions
predicted to contain open-reading frames and the second based
upon defined fragments of the BAC purified from restriction
digests. Targeted disruption by homologous recombination (BAC
recombineering [16]; Table S6) at eight predicted coding regions
(identified by similarity to other annotated genes or EST sequences
and clusters of candidate open reading frames; Figure 5C)
created a panel of eight otherwise unaltered EmaxBAC2k08
versions (Figure S1 and S2). The capacity of each daughter BAC
to confer W-strain-specific protective immunity was tested by
immunisation using the BAC transfection immunisation route
followed by challenge with W strain parasites. For seven of the
eight disrupted BACs no significant change in oocyst output was
obtained compared with immunisation with the unmanipulated
parent BAC. When region 7 was disrupted the protective effect
was reduced to zero indicating that the important antigen or
controlling element was associated with this region (Figure 5D).
When the regions flanking region 7 (6 and 8) were disrupted a
small, but non-significant reduction in oocyst output was observed,
possibly resulting from disruption of associated controlling or
stabilising sequences. In parallel we analysed purified BAC sub-
Figure 3. Fine mapping locus 1 correlated with susceptibility to strain-specific immune killing. (A) The distribution of strain-specific AFLP
markers lost under immune selection across BAC EmaxBAC8f18. Solid markers remained absent after six generations of backcrossing under selection,
hollow marker E031 reappeared in backcrossed generation four. (B) Recovery of strain-specific markers by immune selected backcross generations 1–
6, the number represents the generation at which the marker first reappeared, 2=did not reappear. (C) Transcribed sequences identified within
locus 1 (ST=putative sulphate transporter, AMA-1=apical membrane antigen 1 homologue, TEF=putative transcription elongation factor).
doi:10.1371/journal.ppat.1001279.g003
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which yielded ,63.7 and ,22.4 Kb fragments of the insert
separate from the vector, the smaller fragment including the
candidate disrupted region. Immunisation using H strain sporo-
zoites transiently transfected with either BAC fragment confirmed
the induction of a cross-protective immune phenotype associated
with the smaller but not the larger fragment (40% and 216%
protection respectively compared to a randomly selected BAC
control). Similarity-led gene annotation suggested the presence of
two coding sequences within the ,22.4 Kb locus. More detailed
scrutiny using a locus-wide NimbleGen tiling array with cDNA
derived from E. maxima W strain sporozoites, merozoites
(harvested 67 hours post infection, hpi) and chicken intestine
centred on Meckel’s diverticulum without infection or 6 and
16 hpi with 1610
6 W strain oocysts, revealed four sequences
transcribed by the stages tested (Figure 5E–G). Although
eimerian lifecycles are relatively complex [5], the choice of
lifecycle stages to be sampled was informed by quantitative PCR-
based enumeration of E. maxima replication in naive and
immunised Line C chickens, which revealed the first 24 hpi to
cover the period of most immune killing during homologous
challenge (,88% reduction at 20 hpi; Figure S3). Examination
of the array-identified transcribed sequences revealed (i) a putative
non-coding RNA, (ii) an unknown coding sequence, (iii) a putative
cyclophilin-RNA interacting protein and (iv) a SCY kinase-related
protein (FN813225–8). LD PCR amplicons covering each
predicted W strain coding sequence and flanking regions,
including a section of repeats not found to be transcribed but
identified as a cross-reactive feature by the array, were used in the
BAC transfection immunisation assay. Protective immunity
against W strain challenge was only evident with the unknown
coding sequence (Figure 6). To confirm the protective capacity of
this antigen, which we now term ‘immune mapped protein-1’
(IMP-1), we produced and purified bacterially-expressed protein
and vaccinated Line C chickens. E. maxima IMP-1 recombinant
protein induced 45% immune protection against challenge by the
W strain as judged by reduction in oocyst output (compared with
the thioredoxin protein control, 50% compared with the
unimmunised control; Figure S4). Comparison between the H
and W IMP-1 coding sequences revealed five nucleotide
polymorphisms, two of which yield non-synonymous changes in
amino acid sequence.
Interrogation of the IMP-1 sequence using identification/
prediction platforms including Phobius [17], SignalP [18], and
Figure 4. Immunising ability of individual genes identified within immune mapped locus 1. Average oocyst output per bird following
Eimeria maxima W strain challenge of birds not previously immunised (none), mock immunised (mock) or immunised using the putative sulphate
transporter (ST), apical membrane antigen-1 (AMA-1) or transcription elongation factor (TEF) mapped antigens. Blue bars indicate candidates
presented as E. maxima H strain vectored transgenes (mock=E. maxima H strain transfected in the absence of transgene DNA). Dark red bars indicate
candidates presented as DNA vaccines (mock=empty vaccine vector). Green bars indicate candidates delivered as purified, E. coli-expressed,
thioredoxin-tagged recombinant proteins (mock=thioredoxin only). nd=not done. Bars marked with different letters were significantly different
within each immunisation strategy (p,0.05).
doi:10.1371/journal.ppat.1001279.g004
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recognisable domains. Nonetheless, predicted homologues can be
identified within the genomes of other coccidial parasites including
E. tenella (2e-87; FN813229; NCBI BLASTp2seq [20]), Toxoplasma
gondii (XM_002370108; 2e-36) and Neospora caninum (GeneDB
NCLIV_000430; 4e-37), all of which share a common intron/
exon structure (Figure S5). Further work on the biology of IMP-1
and the eimerian AMA-1 may reveal characteristics common to
molecules that are capable of inducing strong protective immunity.
Overall, our finding that just six regions of the genome were
affected by strong immune selection is important since it suggests
that protective immunity is focussed on a limited repertoire of
parasite antigens. The genome of Eimeria spp. is estimated to be
between 55 and 60 Mbp in size, encoding 8,000–9,000 genes
(http://www.genedb.org/Homepage/Etenella), and the adaptive
immune system recognises a large number of antigens. Our data
indicate, in this precisely controlled genetic context, that natural
infection-induced protective immunity is focussed on the recogni-
Figure 5. Fine mapping locus 5 correlated with susceptibility to strain-specific immune killing. (A) The distribution of strain-specific AFLP
markers lost under immune selection across BAC EmaxBAC2k08. (B) Recovery of strain-specific markers by immune selected backcross generations
revealed that the entire BAC encoded-region remained absent in all generations (2). (C) Regions 1–8 selected for disruption by BAC recombineering.
(D) The influence of targeted disruption on the ability of W strain-derived EmaxBAC2k08 to confer cross-protective immunity when delivered by the
heterologous Eimeria maxima H strain following transient transfection: the protective capacity retained by each recombineered BAC compared to the
unmodified parent BAC. Bars marked with different letters were significantly different (p,0.05). (E–F) Relative fluorescence (rf) illustrating cDNA
hybridisation to a BAC-tiling NimbleGen array covering ,22.4 Kb of locus 5 corresponding to the smaller Not I/Sfi I BAC digest product. (E) cDNA
derived from sporozoite (blue) and merozoite (67 hpi; red) lifecycle stages. (F) Profiles calculated from rf using cDNA derived from uninfected chicken
intestinal tissue subtracted from chicken intestinal tissue 6 (blue) and 16 (red) hours post infection. (G) Transcribed sequences identified within locus
5 (repeats=a repetitive region, no evidence of transcription by targeted lifecycle stages, CRIP=putative cyclophilin-RNA interacting protein,
RP=related protein.
doi:10.1371/journal.ppat.1001279.g005
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the parasite. This feature of antigenically complex pathogens has
troubled those involved in vaccine development for many years.
Our finding that strain-specific immunity against E. maxima is
absolutely targeted against just six loci is comparable with the
number identified with murine malaria [21] and highlights the
concept that antigenically complex pathogens may only express
small numbers of protective antigens. This feature of immunity
may explain the lack of success in developing effective sub-unit
vaccines against antigenically complex pathogens despite decades
of effort directed at using immunodominant antigens. Indeed,
although measurable responses will be directed against ‘‘protective
antigens’’, responses against ‘‘non-protective’’ or ‘‘poorly protec-
tive’’ antigens obscures effective antigen selection. Using response
as the major selection criterion in antigen discovery pipelines
confers high rates of false positive leads. Protection is a much more
discriminatory tool that can be interrogated using a technically
straightforward genetic mapping approach, focussing discovery on
‘‘protective antigens’’ and importantly supporting simultaneous
consideration of all elements of the pathogen, identifying ‘‘sets of
antigens’’ responsible for strong protective immunity. Understand-
ing the basis for discrimination of antigenic molecules that
stimulate ineffective responses from those that stimulate protective
responses has the potential for impact far beyond the scope of this
project.
In this report we document the application of a genetic
approach to discover two protective antigens, one of which
encodes an eimerian homologue of AMA-1 and the other a new
vaccine candidate, IMP-1. The former raises an interesting
possibility that there are features of certain molecules that
confer sensitivity to protective immune responses across a wide
range of Apicomplexa. Interestingly, homologues of the IMP-1
gene can be readily identified in non-eimerian apicomplexan
parasites and these may also be candidate protective antigens.
Three of the other four loci contain elements that confer strain
specific protective immunity (by BAC transfection-immunisation
studies) and it is likely that these also contain protective
antigens. One alternative is that these regions may exert their
effects indirectly (for example by regulation of other non-
polymorphic loci) although at present this seems unlikely. The
nature of the protective effects encoded by the remaining loci is
the focus for ongoing studies. We propose that our strategy will
contribute to development of new anti-eimerian vaccines and
may have much broader impact on the development of vaccines
against some of the most devastating parasitic diseases of
humans and livestock.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the Animals
(Scientific Procedures) Act 1986, an Act of Parliament of the
United Kingdom. All animal studies and protocols were approved
by the Institute for Animal Health Ethical Review Committee and
the United Kingdom Government Home Office under the project
licences 30/2047 and 30/2545.
Figure 6. Immunising ability of individual genes identified within immune mapped locus 5. Average total Eimeria maxima W strain oocyst
output per bird following challenge of birds immunised with E. maxima H vectored W strain transgenes identified within locus 5 presented as
genomic LD-PCR amplicons. None=control, no immunisation, mock=control immunisation with no transgene, CRIP=putative cyclophilin-RNA
interacting protein, RP=related protein. Bars marked with different letters were significantly different (p,0.05).
doi:10.1371/journal.ppat.1001279.g006
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The E. maxima Houghton (H, sensitive to dietary robenidine)
and Weybridge (W, resistant to 66 ppm dietary robenidine) strains
were used as the parental parasites in these studies. Oocysts were
propagated and genetic crosses were carried out in vivo as described
previously [6].
Experimental design: Genetic crosses and selection of
progeny populations
Uncloned populations of hybrid parasites were derived from
eight independent crosses between the H and W E. maxima
strains in Line C White Leghorn chickens as described
previously ([6]; oocysts recovered from between two and ten
birds and pooled for each population). Hybrid sub-populations
were derived from each cross following in vivo passage under a
double selective barrier comprising W strain-specific immune
(induced by previous infection with 100 oocysts of the pure W
strain) and H strain-specific drug (66 ppm robenidine) selection
[6]. All eight first generation selected parasite populations,
together with four serially-selected populations (three to five
rounds of selection, two to ten birds pooled per population per
generation), were used to prepare the parasite mapping panel
(Table S2).
One selected parasite population was backcrossed six times
under double barrier selection, each backcross generation derived
after in vivo phases of (i) cross fertilisation: in vivo passage using 100
sporulated hybrid oocysts with 400 sporulated W (immune-
targeted) parental strain oocysts and (ii) selection: passage of
10,000 sporulated recovered parasites per bird under double
barrier selection. Parasites recovered from ten birds were pooled
for each backcross stage.
Experimental design: In vivo protection trials
Experiments to measure immune protection induced by (i)
immunisation through previous parasite exposure, (ii) recombinant
protein or (iii) DNA vaccination followed standardised protocols.
All treatment groups comprised six individually caged specific
pathogen free Line C White Leghorn chickens. Total daily oocyst
excretion per bird was determined following daily faecal collection
from days 6–7, 7–8 and 8–9 post infection by flotation in saturated
salt solution using a modified McMaster protocol as described
previously [6]. All experiments included a non-immunised control
group.
(i) Previous parasite exposure. Three week old chickens were
immunised by oral infection with 100 sporulated E. maxima
oocysts (wild type) or 1.0610
6 transfected E. maxima
sporozoites (following oral gavage with 0.5 ml 5% w/v
sodium bicarbonate solution; drug cleared three days post
immunisation by inclusion of dietary robenidine at 66 ppm
for three days). Six week old chickens were challenged with
250 sporulated E. maxima oocysts unless stated to be
otherwise.
(ii) Recombinant protein. Two week old chickens were
immunised subcutaneously using 100 mgP B S - d i a l y s e d
recombinant protein in TiterMax Gold adjuvant (Sigma-
Aldrich Ltd.) at two sites in the neck. Chickens were
subsequently re-immunised at three and four weeks of age
(as before but in Freund’s Incomplete adjuvant; Sigma-
Aldrich Ltd.) prior to challenge with 250 sporulated E.
maxima oocysts when six weeks old. Unimmunised, PBS
alone and PBS-dialysed thioredoxin were included as
negative control groups.
(iii) DNA. Two week old chickens were immunised by
intramuscular injection using 50 mg DNA vaccine plasmid
in sterile phosphate buffered saline (pH 7.6) at two sites in
the thigh. Chickens were subsequently re-immunised at
three and four weeks of age (as before) in alternating legs
prior to challenge with 250 sporulated E. maxima oocysts
when six weeks old. TE alone and vector pcDNA3.1(+)
(Invitrogen) were included as negative controls in addition to
an unimmunised group. Tissue excised from the immuni-
sation site post-mortem from one extra bird per group seven
days post-final immunisation was processed to extract total
RNA using the Qiagen RNeasy mini kit (Qiagen) for cDNA
preparation and PCR to confirm DNA vaccine transcription
(data not shown).
Recombinant protein vaccine preparation
cDNA sequences corresponding to the predicted AMA-1
ectodomain and IMP-1 proteins (loci 1 and 5 respectively:
AMA-1 coding nucleotides 79–1,347, IMP-1 161–1,275) were
amplified from E. maxima W strain sporozoite cDNA, cloned into
the expression vector pET32b (Novagen) using Bam HI/Hind III
and Nco I/Eco RI restriction sites respectively and sub-cloned in E.
coli BL21(DE3)pLysS (Novagen). Recombinant proteins were
expressed and purified using HisTrap FF purification columns
(GE Healthcare) as described by the manufacturer, dialysed
overnight against PBS and finally mixed with an equal volume of
adjuvant shortly before use. Thioredoxin expressed in the same
manner using the unmodified pET32b vector was purified and
used as a negative control.
DNA vaccine preparation
cDNA sequences corresponding to the predicted AMA-1
ectodomain and sulphate transporter proteins (locus 1: AMA-1
coding nucleotides 79–1,347, sulphate transporter 1–2,988) were
amplified from E. maxima W strain cDNA, cloned into the
eukaryotic expression vector pcDNA3.1(+) (Invitrogen) using Hind
III/Bam HI restriction sites and sub-cloned in E. coli XL1-Blue
MRF (Stratagene). Plasmid DNA was purified using the Qiagen
EndoFree Plasmid Maxi kit as recommended by the manufacturer
(Qiagen), precipitated and re-suspended in endotoxin-free TE at
250 mg/ml.
Nucleic acid resources
Genomic DNA was extracted from oocysts as described
previously using a physical smashing step followed by phenol/
chloroform extraction [22] and from chicken intestinal tissue
samples using a Qiagen DNeasy tissue kit as described by the
manufacturer (Qiagen) followed by RNase A treatment [23]. Total
RNA was purified from E. maxima sporozoite, merozoite (harvested
67 hours post infection), infected and uninfected chicken intestinal
tissue using a Qiagen RNeasy kit as described by the manufacturer
[24]. A BAC library was constructed for the E. maxima W strain in
the pBACe3.6 vector following the protocol of Osoegawa et al [25]
based upon chromosomal DNA prepared from E. maxima
sporozoites as described elsewhere [26]. BAC DNA was prepared
using the Qiagen Large-Construct kit as described by the
manufacturer (Qiagen).
Standard PCR amplification was completed using BIO-X-ACT
Short DNA Polymerase (Bioline Ltd.). Each PCR reaction
contained 5 ng template DNA, 20 pmol of relevant forward and
reverse primers, 0.5 U Taq polymerase, 10 mM Tris–HCl,
1.5 mM MgCl2, 50 mM KCl and 0.2 mM dNTPs. Standard
cycle parameters were 16(5 min at 94uC), 306(1 min at 94uC,
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For LD PCR BIO-X-ACT Long DNA Polymerase (Bioline Ltd.)
was used as recommended by the manufacturer. Where required
cDNA was prepared using Invitrogen Superscript II reverse
transcriptase and oligo dT as described by the manufacturer
(Invitrogen Ltd.). PCR fragments were cloned using pGEM-T
Easy (Promega) in XL1-Blue Escherichia coli (Stratagene), mini-
prepped (Qiagen) and sequenced (Beckman CEQ 8000 genetic
analysis system) as described by the respective manufacturers.
Sequence assembly, annotation and interrogation were undertak-
en using VectorNTI v11.0 (Invitrogen) except where stated.
Quantification of parasite replication
Groups of four inbred SPF Line C White Leghorn chickens
were either left naive or were immunised by infection with 100
sporulated E. maxima W strain oocysts at three weeks of age. All
birds were subsequently challenged by infection with 1.0610
6
E. maxima W strain oocysts at six weeks of age (homologous
challenge). Unimmunised and immunised groups were culled at 0,
2, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48 and 72 hours post challenge,
when an 8 cm length of intestine centred on Meckel’s diverticulum
was recovered post-mortem from each test bird and homogenised
in sterile TE using a Qiagen TissueRuptor (230 V, 50/60 Hz).
Total genomic DNA was extracted from three 25 ml aliquots of
each sample using a Qiagen AllPrep DNA/RNA Mini kit as
described by the manufacturer (Qiagen). The total number of
E. maxima genomes per host genome was determined from each
sample using TaqMan quantitative PCR assays specific for the
E. maxima microneme protein 1 (MIC1) and chicken glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) loci in duplex with
the 7500 Fast Real-Time PCR System (Applied Biosystems) [23].
TaqMan probes were 59 labeled with FAM (MIC1) or Yakima
Yellow (GAPDH) and 39 quenched with Eclipse Dark Quencher
(Eurogentec). TaqMan conditions and cycle parameters were
modified from the standard Applied Biosystems Fast protocol
(1695uC, 20 s; 40695uC, 15 s and 60uC, 30 s). Quantitative
calculations were facilitated and validated by comparison with
known concentrations of the relevant genomic DNA template.
Genetic marker production
AFLP was used to generate the majority of the genetic markers
used during these studies as described elsewhere [27]. Approxi-
mately 50 ng total E. maxima genomic DNA was digested using
one of five restriction enzyme combinations (Table S1; New
England Biolabs) prior to ligation to adapters derived from those
described by Vos et al, adapted for the respective restriction
enzyme [27]. Primer pairs (MWG Biotech (UK) Ltd.) were based
on the adaptor sequences and provided 0 and 1 (primary
amplification) or 1 and 2 (secondary amplification) selective bases,
respectively. Markers of interest were gel excised, re-amplified,
cloned and sequenced as described previously [6]. Marker specific-
primers were designed using Primer3 to amplify marker-associated
DNA fragments [28].
Additional genetic markers were developed by sequencing 600–
750 bp sections of E. maxima H strain genomic DNA correspond-
ing to targets distributed across each locus mapped in the W strain
(Table S4 for the primers used, FN813230–41). Strain-specific
primer pairs were developed following sequence alignment and
SNP identification (ClustalX [29]; Table S5).
Pulsed field gel electrophoresis
Chromosomal karyotypes were resolved by PFGE. Briefly,
E. maxima W strain chromosomal DNA in ,4m m 63m m 62m m
sections cut from an agarose block [26] was separated in a 0.8%
SeaKem HGT agarose gel (Lonza) prepared in 0.56Tris–borate
EDTA (TBE) buffer and subjected to PFGE in a 21 cm614 cm
gel using a CHEF DRII system (Bio-Rad) in 2 L of 0.56TBE
running buffer at 14uC. PFGE conditions were (i) 216 h at
1.3 volts/cm with a switch time of 3,000–3,500 s followed by (ii)
120 h at 1.3 volts/cm with a switch time of 3,300–3,600 s
finishing with (iii) 48 h at 1.2 volts/cm with a switch time of
3,200–3,400 s. Gels were stained in a 0.5 mg/ml aqueous solution
of ethidium bromide for 30 min, destained in water and then
photographed. Hansenula wingei and Schizosaccharomyces pombe DNA
plugs (Bio-Rad) were included as size markers.
Individual BAC clone insert size was determined by Not I (New
England Biolabs) digestion followed by PFGE in 1% Bio-Rad
pulsed field certified agarose prepared in 0.56TBE as above.
PFGE conditions were 18 h at 4 volts/cm with a switch time of 1–
6 s. Low range PFG size markers (New England Biolabs) were
included as size markers.
DNA hybridisation
PFGE-resolved chromosomal DNA was transferred to Hybond-
N+ membrane (Amersham Biosciences) as recommended by the
manufacturers. A total of 3072-BAC transformed E. coli DH10B
were robotically gridded onto replicated filter arrays providing
,7.5-fold coverage of the E. maxima W strain genome. PCR
products derived from AFLP markers of interest were labelled with
32P using a Prime-It II random priming kit (Stratagene) and
hybridised to filters for 16–24 h at 65uC as described by
Amersham Biosciences. Filters were washed three times at 65uC
in 0.16SSC before exposure to X-ray film (Kodak BioMax MS) at
280uC against intensifying screens.
BAC sequencing, assembly and annotation
BAC DNA was prepared from clones identified by hybridisation
to AFLP markers of interest using the Qiagen Large-Construct kit
as recommended by the manufacturer. Small insert libraries (2–
4 Kb) were prepared by shearing the DNA by sonication, blunt
ending and size selecting by agarose gel electrophoresis prior to
sub-cloning into Sma I digested dephosphorylated pUC18 for use
in a whole-BAC shotgun sequencing strategy. ABI PRISM BigDye
Terminator (Applied Biosystems) forward and reverse plasmid end
sequences generated using an ABI3730 capillary sequencer were
assembled using the Staden-based PHRAP (P. Green, unpub-
lished). Contig assembly was based upon LD PCR.
Preliminary annotation of each assembled BAC sequence was
achieved using tBLASTx [20] interrogation of all publically
accessible sequences through the National Center for Biotechnol-
ogy Information (NCBI, http://www.ncbi.nlm.nih.gov/), supple-
mented by Eimeria species EST data from the Eimeria ORESTES
and E. maxima EST sequencing projects (Gruber and Madeira,
unpublished; Wan and Blake, unpublished, respectively). All
sequences produced in this study have been submitted to EMBL,
where they are available under the accession numbers FN813211–
44.
BAC recombineering
The E. coli DY380 strain [16] (kindly supplied by the National
Cancer Institute, Frederick, USA) was initially transformed with E.
maxima W strain BAC EmaxBAC2K8 as described elsewhere [30].
Subsequently, the DY380/EmaxBAC2K8 line was transformed
with each of eight PCR products representing (i) unique
EmaxBAC2K8 sequences for targeted homologous recombination
and (ii) the b-lactamase coding sequence amplified from pGEM-T
Easy (Promega; primers as shown in Table S6; PCR as above,
purified using the Qiagen Gel Extraction kit as described by the
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cloned and tested for evidence of correctly targeted insertion in a
pure clonal line and the absence of widespread BAC disruption by
(i) positive PCR between insert and flanking BAC sequences
(Figure S1), (ii) negative PCR between target and flanking BAC
sequences (Figure S1, primers shown in Table S7) and (iii)
unchanged BAC PFGE profile following Not I/Sfi I digestion
(Figure S2; enzymes New England Biolabs).
Transfection
E. maxima W strain genomic DNA, presented as whole,
recombineered or partial BAC-encoded templates or LD PCR
amplicons, was used to transiently transfect the E. maxima H strain.
For whole and recombineered BAC transfection purified plasmid
DNA was re-suspended at 50 mg/10 ml TE. BAC EmaxBAC2k08
was subdivided by Not I/Sfi I digestion (New England Biolabs) and
subsequent PFGE (as above), yielding ,63.7 and ,22.4 Kb
fragments of the insert as well as the vector. The 63.7 and 22.4 Kb
fragments were gel excised following large-scale PFGE, electro-
eluted into dialysis bags in TE, precipitated and re-suspended at
37 and 13 mg/10 ml respectively in TE as described elsewhere
[31]. LD PCR amplicons representing three EmaxBAC8f18
candidate regions and four EmaxBAC2k08 regions were amplified
in triplicate, (primers shown in Table S8, designed to lie.1K b
outside any BLAST hit with an E value of 1e-05 or below or to
yield an amplicon.7 Kb in size across the predicted coding
sequence, whichever was the greater). All triplicates were
electrophoresed to check for purity and target size, identified by
test secondary PCR (Table S8), pooled once validated, precip-
itated and re-suspended in 10 ml TE [31].
Transient transfection was accomplished following a protocol
modified slightly from that described previously [10]. Briefly,
freshly excysted and purified E. maxima H strain sporozoites were
washed in incomplete cytomix and re-suspended in AMAXA Basic
Parasite Nucleofector Solution 2 at 3.0610
7/ml immediately prior
to nucleofection. Subsequently, 100 ml sporozoite suspension was
mixed with 10 ml DNA at room temperature, transferred to a
cuvette and nucleofected as described by the manufacturer using a
Nucleofector II with program U-033 (Lonza). Post-nucleofection
all sporozoites were immediately re-suspended in 3 ml PBS+1%
glucose (w/v) and left to rest for 20 mins at room temperature.
Sporozoites were then either used as an oral dose to initiate in vivo
infection or incubated overnight at 41uC in a 5% CO2 incubator.
For oral dosing the output from two nucleofections were pooled
and dosed using 1.0610
6 sporozoites (counted pre-nucleofection)
per bird. Total RNA was extracted from incubated sporozoites
using the Qiagen RNeasy mini kit for cDNA preparation and
PCR of one or more transfected DNA-specific transgenes to
confirm transfection (data not shown).
BAC tiling array
A custom-made NimbleGen genome tiling array containing
79,955 50–75 bp probes (presented as forward and reverse strands
in duplicate) was designed and produced using BAC sequences
obtained during these studies (Roche). E. maxima W strain genomic
DNA covered by BACs EmaxBAC8f18 and EmaxBAC2k08 were
represented by 9,798 and 7,387 probes respectively (Emax-
BAC8f18: 8,321 unique, 1,477 twice, 84.5% coverage; Emax-
BAC2k08: 7,315 unique, 72 twice, 95.5% coverage). Total RNA
extracted from purified E. maxima W strain sporozoites, merozoites
(harvested 67 hpi), uninfected chicken intestinal tissue sampled at
Meckel’s diverticulum and chicken intestinal tissue sampled 6 and
16 hpi with 1610
6 E. maxima W strain oocysts were processed to
produce labelled cDNA and hybridised to the array as described
by the manufacturer (Roche). Arrays were scanned using a
GenePix 4000B scanner and the images were visualised using
GenePix Pro software (Axon). Array design was viewed using
NimbleGen SignalMap v1.9 software. Arrays were read using
NimbleGen NimbleScan v2.5 software with alignment and
uniformity cut off points of 0.15 and 0.3 respectively.
Statistics
Arithmetic mean and associated standard error of the mean
(SEM) for each sample or group were calculated using Excel
(Microsoft Excel 2002, Microsoft Corporation, 2001). Statistical
analyses were performed using the t-test, ANOVA, Chi
2 or
Kruskal-Wallis tests in Minitab (Minitab Release 14, Minitab Inc.,
2003), complimented by post hoc analysis using the Tukey’s test.
Differences were deemed significant with a p value,0.05.
Accession numbers
Supporting Information
Figure S1 PCR confirmation of targeted EmaxBAC2k08
disruption by recombineering for eight selected regions (1–8).
PCR assays confirming the targeted insertion of the recombineer-
ing cassette (knockout: k/o) and the absence of unmodified BAC
copies (wild type: wt). +=recombineered candidate BAC,
2=unmodified original BAC.
Found at: doi:10.1371/journal.ppat.1001279.s001 (0.30 MB TIF)
Figure S2 Demonstration of the absence of gross BAC
conformational change following recombineering. PFGE resolu-
tion of Not I/Sfi I digested unmodified EmaxBAC2k08 (lane 1) and
EmaxBAC2k08 recombineered to disrupt regions 1–8 (lanes 2–9).
Found at: doi:10.1371/journal.ppat.1001279.s002 (1.71 MB TIF)
Sequence ID Acc. No.
Eimeria maxima AFLP fragments FN813211–
FN813218
Eimeria maxima partial mRNA for putative sulphate
transporter, strain Weybridge
FN813219
Eimeria maxima partial mRNA for putative sulphate
transporter, strain Houghton
FN813220
Eimeria maxima mRNA for putative apical membrane
antigen-1 (ama-1 gene), strain Weybridge
FN813221
Eimeria maxima mRNA for putative apical membrane
antigen-1 (ama-1 gene), strain Houghton
FN813222
Eimeria maxima partial mRNA for putative transcription
elongation factor (tef gene), strain Weybridge
FN813223
Eimeria maxima partial mRNA for putative transcription
elongation factor (tef gene), strain Houghton
FN813224
Eimeria maxima EST, strain Weybridge, clone
EmaxBAC2k08_NIM1_W
FN813225
Eimeria maxima EST, strain Houghton, clone
EmaxBAC2k08_NIM1_H
FN813226
Eimeria maxima mRNA for IMP1 protein, strain Weybridge FN813227
Eimeria maxima mRNA for IMP1 protein, strain Houghton FN813228
Eimeria tenella mRNA for IMP1 protein, strain Houghton FN813229
Eimeria maxima SCAR fragments FN813230–
FN813241
Eimeria maxima BAC clone EmaxBAC7a02 FN813242
Eimeria maxima BAC clone EmaxBAC8f18 FN813243
Eimeria maxima BAC clone EmaxBAC2k08 FN813244
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maxima W strain replication revealed by qPCR. In vivo intracellular
E. maxima W strain replication in naı ¨ve (red, solid line) and
previously infected (homologous infection; blue, broken line)
chickens. Total parasite genome numbers determined for an 8 cm
intestinal section centred upon Meckel’s diverticulum. Region A
highlights the first significant difference in parasite replication
between the immunised and unimmunised host. Importantly, whilst
qPCR-detected parasite genome numbers are not equivalent to
viable parasites, the residual parasite genomes detected after 20 hpi
in the immune host were not seen to replicate and were unlikely to
represent live parasites. Thus, regions A and B represent the period
when immune killing must have occurred. *p,0.01, **p,0.005.
Found at: doi:10.1371/journal.ppat.1001279.s003 (0.22 MB TIF)
Figure S4 Anticoccidial protective capacity of Eimeria maxima
IMP-1. Anticoccidial protection induced by vaccination with
recombinant E. maxima IMP-1 compared with thioredoxin, PBS
and no immunisations (protein, immunisation and environmental
controls respectively). Bars marked with different letters were
significantly different (p,0.01, ANOVA + Tukey’s post hoc).
Found at: doi:10.1371/journal.ppat.1001279.s004 (0.14 MB TIF)
Figure S5 Putative apicomplexan IMP-1 homologues. (a) IMP-1
intron/exon structure from Eimeria maxima (FN813225), Eimeria
tenella (FN813229), Toxoplasma gondii (XM_002370108) and Neos-
pora caninum (NCLIV_000430; GeneDB). (b) Full length IMP-1
alignment using sequenced (E. maxima) or predicted (others)
translated coding sequences.
Found at: doi:10.1371/journal.ppat.1001279.s005 (1.15 MB TIF)
Table S1 Frequency of five AFLP marker inheritance patterns.
H parent specific, negative selection=66 ppm dietary robenidine.
W parent specific, negative selection=W strain-specific immunity
induced by previous W strain infection. No significant difference
was noted in the number of strain-specific markers amplified from
either parental strain (Chi
2 test). No significant bias was detected
in the identification of negatively selected markers between the
enzyme combinations (Kruskal-Wallis test).
Found at: doi:10.1371/journal.ppat.1001279.s006 (0.03 MB
DOC)
Table S2 The Eimeria maxima mapping panel. nr=not relevant.
Found at: doi:10.1371/journal.ppat.1001279.s007 (0.03 MB
DOC)
Table S3 Transient EimeriamaximaBAC transfection: Utility for in
vivo immunisation and phenotypic screening for associated
immunoprotective capacity. Immunisation included infection fol-
lowed by drug clearance three days later using dietary robenidine
(66 ppm). Challenge doses were administered three weeks after the
immunisingdose.Figureswithineachtrialannotated witha different
superscript letter were significantly different (p,0.05; ANOVA +
Tukey’s post hoc). *Control BAC=EmaxBAC4c21, **Test BA-
C=EmaxBAC2k08, mapped to locus 5. NF=none found.
Found at: doi:10.1371/journal.ppat.1001279.s008 (0.04 MB
DOC)
Table S4 Primers for PCR amplification of equivalent Eimeria
maxima H strain regions to identify polymorphic markers across
locus 1 (BAC EmaxBAC8f18).
Found at: doi:10.1371/journal.ppat.1001279.s009 (0.03 MB
DOC)
Table S5 W strain-specific primers for genotyping backcrossed
populations (derived using sequences from Table S4). Upper case
letters are polymorphic between the Eimeria maxima H and W
strains.
Found at: doi:10.1371/journal.ppat.1001279.s010 (0.04 MB
DOC)
Table S6 BAC recombineering strategy. BAC recombineering
constructs created by PCR amplifying a selectable cassette (b-
lactamase, using pGEM-T Easy as template, primer sequences A)
incorporating unique BAC sequences for targeted recombination
(sequences B).
Found at: doi:10.1371/journal.ppat.1001279.s011 (0.06 MB
DOC)
Table S7 Validation of targeted BAC recombineering by PCR.
Primers designed to confirm targeted disruption: knockout=am-
plification between target-flanking genomic DNA and the insert,
wild-type=amplification between target-flanking genomic DNA
and the genomic DNA target. Results shown in Figure S4.
Found at: doi:10.1371/journal.ppat.1001279.s012 (0.04 MB
DOC)
Table S8 EmaxBAC8f18 and EmaxBAC2k08 specific primers for
LD PCR and nested PCR to confirm LD PCR amplicon identity.
*Putative annotation.
Found at: doi:10.1371/journal.ppat.1001279.s013 (0.03 MB
DOC)
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